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Interactions between mucosal surfaces and microbial microbiota are key to host defense, health, and disease. These surfaces are
exposedtohighnumbersofmicrobesandmustbecapableofdistinguishingbetweenthosethatarebeneﬁcialoravirulentandthose
that will invade and cause disease. Our understanding of the mechanisms involved in these discriminatory processes has recently
begun to expand as new studies bring to light the importance of epithelial cells and novel immune cell subsets such as Th17 T
cells in these processes. Elucidating how these mechanisms function will improve our understanding of many diverse diseases
and improve our ability to treat patients suﬀering from these conditions. In our voyage to discover these mechanisms, mucosal
interactions with opportunistic commensal organisms such as the fungus Candida albicans provide insights that are invaluable.
Here, we review current knowledge of the interactions between C. albicans and epithelial surfaces and how this may shape our
understanding of microbial-mucosal interactions.
1.Introduction
Fungaldiseasesbecamerecognisedasbeingofclinicalimpor-
tance in the second half of the last century largely due to a
combination of rising numbers of patients with immunode-
ﬁciency illnesses such as HIV infections, advances in medical
treatments such as cancer therapy and transplantation, and
improvements in general life expectancies. The incidence of
fungal infections has increased dramatically over the past
two to three decades and this trend will inevitably continue
into the 21st century, particularly as further improvements
are made in health care for immunocompromised patients.
Thus, these infections will become an increasingly pressing
problem with ever mounting cost pressures on national
health facilities.
Candida species are the most common fungal pathogens
of humans and the causative agents of oral, gastrointestinal,
and vaginal candidiasis, giving rise to severe morbidity in
millions of individuals worldwide. Vaginal candidiasis alone
aﬀects ∼75% of women at least once during fertile age [1, 2],
equating to ∼30 million infection episodes/year. Candida
infections are also the most common oral manifestation
of HIV infection, with 50% of HIV+ patients and 90%
AIDS patients suﬀering from oral candidiasis [3–5]. With
∼4 million cases of HIV/year, this equates to ∼2 million oral
candidiasis cases/year. Indeed, one of the biggest killers of
the immunocompromised population is fungal infection.
Candida species also cause mucosal diseases in the elderly
and edentulous individuals, such as Candida-associated
denture stomatitis. Furthermore, depending on the study,
Candida infections are also the 3rd or 4th most common
hospital-acquired bloodstream infection, making Candida
speciesasmedicallyimportantasmanymainstreambacterial
infections including Enterococci (E. coli) and Pseudomonas
spp [6, 7]. In the USA, yearly healthcare costs for systemic
fungal infections are ∼ $2.6 billion, of which Candida
infections account for ∼ $1.8 billion [8]. European Union
healthcare costs are estimated to be similar. Furthermore,
whentakingintoaccountmucosalinfections,truehealthcare
costs are likely to be far higher, although precise ﬁgures are
scarce. Therefore, Candida pathogens carry an immense
health burden and represent a major socioeconomic cha-
llenge for worldwide communities.
Therefore, it is important to understand the mechanisms
involved in host-Candida interactions, particularly those2 Clinical and Developmental Immunology
involved in initiating immune responses and in discrim-
inating between the commensal and pathogenic forms of
this fungus. As such, the interactions of Candida with
cells of the host immune system have been widely studied
with several key reports indicating how Candida and other
fungal species are detected by macrophages, dendritic cells,
and neutrophils. However, given that the vast majority of
Candida infections occur at mucosal surfaces, recent interest
has turned towards investigating the interactions between
Candida and epithelial cells (ECs) and how this might elicit
protective immunity.
2.C. albicans andMucosalSurfaces
With the increases in our knowledge of the human micro-
biome and the interplay with its host, it has become increas-
ingly evident that there exists a highly specialised set of
interactions between host organism, residential microbiota,
and pathogenic microbes. These interactions lead to either
a degree of mutualism in the case of resident, commensal
microbes, or breaches in the epithelial barrier followed by
disease pathology and immune activation in the case of
pathogenic microbes. Exactly how the host discriminates
between commensal and pathogenic microbes is not well
understood but is key to our understanding of health and
disease. Of particular importance is the identiﬁcation of host
mechanisms that discriminate between the commensal and
pathogenic states of “opportunistic” microbes, such as the
fungusCandidaalbicans,asthiswillprovidevaluableinsights
into how we can manipulate host immunity to control such
infections. In particular, understanding these mechanisms
will allow us to understand and potentially manipulate
immunological events that allow chronic infection by this
fungus.
Candida species commonly reside as commensal organ-
isms, being part of the normal microbiome in the gut, oral
cavity, or vagina in approximately 50% of the population.
Although normally these fungi cause no pathology, if there
are changes in the local environment, such as alterations in
normal microbiota or compromised local immune defences,
then these fungi can become pathogenic. As such, they cause
mucosal disease in a signiﬁcant proportion of immuno-
suppressed patients and women of fertile age [2]w i t h
the majority of these individuals experiencing superﬁcial
mucosal candidiasis such as thrush. How the host is able to
recognise this shift and respond to control these infections is
not well understood but has become the subject of growing
research interest. Many putative virulence factors have been
proposed as playing roles in C. albicans infections [9], but
of these the most studied and widely accepted is hypha
formation leading to invasion [10, 11]. What role, if any,
these factors play in host discriminatory responses has,
until recently, been unclear, but studies are beginning to
show an important role for ECs within mucosal surfaces in
this process. Further, the mechanisms that the fungus uses
to allow evasion of acute immune responses, resulting in
chronicinfections,areonlynowbeginningtobeunderstood.
In this paper, we will outline current understanding of the
interactions of C. albicans with mucosal surfaces and discuss
the important role ECs play in this process.
3. Immune Recognition ofC. albicans
The discovery of Toll-like receptors (TLRs) as pattern recog-
nition receptors (PRRs) in the late 1990s lead to a change
in our understanding of how pathogens are recognised by
the immune system. We now understand that as well as
recognition of speciﬁc antigens by T-cells (through the T
cell receptor) in the adaptive immune response, conserved
pathogen associated molecular patterns (PAMPs) are recog-
nised by PRRs as part of the innate immune response. Since
the discovery of TLRs, there has been a rapid expansion of
characterised PRRs that now includes a panoply of diﬀerent
families and individual molecules. These include the main
families of the TLRs, CLRs (C-type lectin receptors), NLRs
(Nacht-like receptors), and RLRs (RIG-like receptors) as
well as a host of other, individual receptor molecules [12,
13]. Diﬀerent locations and cell types throughout the body
also show diﬀerences in the PRRs they express, and, since
each PRR recognises individual PAMPs, this may result in
diﬀering sensitivities of various body locales to the multitude
of microbes that we encounter.
In the case of fungi and particularly C. albicans, the
predominant immune cell types involved in combating
mucosalinfectionareneutrophils[14].Recognitionoffungal
cells by these cells has been the subject of the majority
of antifungal immunity research during the last ten years,
culminating in the discovery of a new PRR, Dectin-1 (β-
1,3 glucan) [15, 16], and identiﬁcation of a role for several
other PRRs involved in recognition of diﬀerent cell wall
polysaccharides of this pathogen, including TLR2 (phos-
pholipomannan),TLR4(O-mannan),andmannosereceptor
(N-mannan) [17–19]( Table 1). These PRRs have been
shown to work both independently and in conjunction with
one another. For example, Dectin-1 and TLR2 play a role
in the recognition of fungal yeasts, each being responsible
for separate actions with Dectin-1 inducing phagocytosis,
whilstTLR2activationinducescytokineproduction[20,21].
Each can act independently, but together they produce a
synergistic response. Although these are the main receptors
used by macrophages and neutrophils, other receptors have
also been identiﬁed, including Dectin-2 [22], mincle [23],
DC-SIGN [24, 25], and galectin-3 [26]. The role of these
receptors is currently not fully established and is thus a focus
of research by diﬀerent groups; however, Dectin-2 and DC-
SIGN have recently been suggested to play an important
role in the recognition of high mannose structures [27]
and galectin-3 in the recognition of β-1,2 mannosides [26]
(Table 1).
4.EpithelialRecognition ofCandida albicans
andInteraction with ImmuneCells
Despite our knowledge of the PRR-mediated interactions
between myeloid cells and C. albicans, the relative impor-
tance of these interactions in the detection of this fungus at
mucosal surfaces is unclear. This is because, when C. albicansClinical and Developmental Immunology 3
Table 1: Pattern recognition receptors that sense fungal-associated PAMPs.
Family Receptor PAMP References
TLRs
TLR2 Phospholipomannan [19]
TLR3 Double-stranded RNA [28]
TLR4 Mannan [29]
O-linked Mannan residues [21]
TLR9 CpG DNA [30]
CLRs
Dectin-1 β-1,3-glucan [16]
Dectin-2 High-mannose structures [31]
α-mannans [22]
Mannose receptor Mannan [32]
MINCLE Unknown [23]
Galectin-3 β-1,2-Mannosides [26]
DC-SIGN High-mannose structures [24]
NLRs NLRP3 Unknown [33]
Others Cdw17 Unknown [34]
colonises a host, there is little evidence that the fungus
interacts directly with neutrophils or macrophages in the
ﬁrst instance, rather the initial interaction is with ECs.
Therefore, the key question is: do ECs utilise the same PRRs
as myeloid cells in the recognition of C. albicans?E C sa r e
known to express a range of PRRs such as TLRs, Dectin-1
and galectins along with their coreceptors and adaptors [35–
37].ExpressionofTLR2andTLR5,inparticular,isexpressed
at high levels by oral ECs, which is notable given that
these receptors have been associated with epithelial growth,
survival, and repair [38, 39]. Interestingly, TLR4 is expressed
at extremely low levels on oral ECs [35], implying that ECs
may be refractory to initial stimulation by TLR4 ligands
such as lipopolysaccharide (LPS) and thus Gram-negative
bacteria. The exact composition of the PRRs utilised by ECs
to recognise C. albicans upon initial infection is currently
unknown. Recently, we demonstrated that TLR2, TLR4, and
Dectin-1 do not appear to be involved in activating epithelial
immunity as blockade or inhibition of these receptors did
not aﬀect the EC cytokine response to C. albicans [40].
This is supported by another study showing a lack of TLR4
involvementintheinductionofGM-CSFbyC.glabrata[41].
Furthermore, although the fungal PAMPs inducing cytokine
responses in myeloid cells are well described, including
mannans and β-glucans, we found that none of these PAMPs
ortheotherpolysaccharideconstituentofthefungalcellwall,
chitin, induced cytokine responses in oral ECs [40]. This
was also recently demonstrated for skin keratinocytes [42].
Together, these studies suggest that ECs may utilize diﬀerent
receptors for immune activation and/or target diﬀerent
fungal moieties than myeloid cells, indicating that epithelial
fungal detection mechanisms may diﬀer from myeloid cell
detection mechanisms.
Despite our knowledge of immune cell- and epithelial-
fungal interactions, the relative importance of each interac-
tion in the context of a mucosal infection is unclear. One
would, however, expect a high level of immunological cross-
talk between the ECs, Candida, and local immune cells in
order to either maintain homeostasis (commensal state) or
to elicit a protective immune response (pathogenic state).
To date, this complex but highly interesting area has largely
been ignored, but recently it has become evident that these
three-way interactions are critical for host defence. One of
the ground-breaking studies in this area was undertaken by
Weindl et al. [37] using a three-dimensional organotypic
oral epithelial model. Such models permit the direct analysis
of pathogen-epithelial interactions that are not complicated
by nonepithelial factors, and, although these models are
not direct mimics of the in vivo environment, they can
be supplemented with immune cells to investigate more
complex cell-cell interactions that are applicable to the in
vivo situation. Using this model, the authors found that
when applied alone, C. albicans induced a chemoattractive
and proinﬂammatory cytokine “eﬀector response” but failed
to signiﬁcantly modulate TLR1-10 expression. However,
addition of PMNs to the Candida-infection model strongly
upregulatedepithelialTLR4expression(∼100-fold)andpro-
tected against C. albicans infection. No signiﬁcant alterations
in TLR1-10 expression or protection were observed when
PMNs were added in the absence of C. albicans. Interestingly,
C. albicans-induced cell damage was abolished irrespective
of whether the PMNs were applied directly to the epithelium
or were separated by a membrane. This demonstrated that
(i) PMN-dependent protection against C. albicans infection
wasindependentofPMNmigrationordirectcell-cellcontact
with the oral epithelium, and (ii) three-way communication
between Candida, EC, and immune cell was essential for
TLR4upregulationandsubsequentprotection.Furtherstud-
ies demonstrated that Candida invasion and cell injury could
be restored by TLR4 blockade or “knockdown” of TLR4
using siRNA, even in the presence of PMNs, demonstrating
a direct role of epithelial TLR4 in antifungal protective
responses. This data is of speciﬁc interest as it demonstrates
that although epithelial TLR4 is not required for the initial
activation of ECs [40], it is required for subsequent epithelial
protection in the presence of immune cells. This is the
ﬁrst description of such a PMN-dependent TLR4-mediated
protective mechanism at epithelial surfaces and may provide4 Clinical and Developmental Immunology
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Figure 1: Signal pathway activation by the main TLR and CLR receptors that detect Candida. Signalling through TLRs proceeds mainly via
TRAF6 with a variety of adaptor proteins acting as intermediaries between receptor and TRAF6. Foremost among these is MyD88 which is
utilised by all known TLRs except TLR3. As well as MyD88, there are other adaptor molecules, including TRIF, MAL, and TRAM, with the
diﬀerent TLRs using diﬀerent combinations of these adaptors. Activation of these adaptors leads to activation of IRAK1, 2, and 4 followed
by ubiquitination of TRAF6 which leads to subsequent activation of downstream signalling pathways. Signalling through CLRs utilises
cytoplasmic ITAM domains to interact with the SYK adaptor molecule, activating the Card-9-Bcl10-Malt1 protein complex. Some CLRs,
such as Dectin-1, include a modiﬁed ITAM domain in their cytoplasmic domain. Others, such as Dectin-2, associate with other receptor
molecules, notably the FcRγ and DAP12 proteins, which possess the ITAM domain that transduces the signal into the cell. In all cases, the
net eﬀect is to activate the MAPK and NF-κB pathways, leading to upregulation of speciﬁc gene transcription. In addition to this, TLRs are
also known to activate transcription via members of the IRF family, including IRF3, IRF5, and IRF7.
signiﬁcant insights into how fungal infections are managed
and controlled in mucosal tissues. It also demonstrates
that far from being bystanders during infections, ECs play
an active and integral role in mucosal protection against
pathogens.
5.EpithelialSignallingDetectionMechanisms
Binding of PRRs by their PAMPs is only the ﬁrst step in the
process of recognition. Ligation of PRRs results in activation
of a collection of diﬀerent intracellular signalling pathways
which in turn lead to alterations in gene transcription and
ultimately changes in protein expression proﬁles. In myeloid
cells, several diﬀerent signalling pathways are activated by
PRR ligation, including the MAPK pathways and the NF-
κBp a t h w a y( Figure 1). The events leading to the activation
of these pathways depend on the triggering receptor. For
example, activation of TLRs such as TLR2 and TLR4 leads
to interaction of their cytoplasmic TIR (Toll/IL-1 receptor)
domain with several diﬀerent adaptor molecules including
MYD88,MAL,TRAM,andTRIF.Thisresultsintheassembly
of a complex of proteins including IRAK1, 2, and 4 with
TRAF6, leading to activation of the MAPK and NF-κB
signalling pathways [43], as well as transcription through
activation of IRF-3, IRF-5, and IRF-7 [44]. Activation of
Dectin-1 and other CLRs leads to activation of similar
pathways, although through diﬀering early mechanisms.
In contrast to the TLR receptors, CLR ligation results in
activation of a CARD9-MALT1-Bcl10 protein complex. This
occurs after phosphorylation of an ITAM-like domain in the
cytoplasmic domain of the CLR (as with Dectin-1) or co-
receptor (e.g., FcRγ for Dectin-2) results in phosphorylation
of SYK [15, 45]. Subsequent to these events is the activation
of both NF-κB and MAPK signalling and downstream
transcriptional events such as activation of the MAPK
transcription factor AP-1 heterodimer. Activation of the
MAPK pathway also leads to activation of a group of phos-
phatasesknownasthedualspeciﬁcityphosphatases(DUSPs)Clinical and Developmental Immunology 5
includingMKP1.Thesephosphatasesacttodephosphorylate
and thus deactivate the MAPK proteins, ERK1/2, p38, and
JNK [46]. As these phosphatases are activated by the MAPK
proteins as a result of MAPK signalling, they form part of
a negative feedback loop to regulate the activity of these
pathways with each DUSP being speciﬁc for a diﬀerent
MAPK protein.
The exact roles of these pathways in normal, healthy
responses to Candida vary depending on the celltype and
the context of the stimulation. Diﬀerent cell types express
varying levels of the relevant transcription factors, resulting
in alternate transcriptional proﬁles being activated. Equally,
the combination of PRRs on the surface of diﬀerent cells will
result in alternate mechanisms being activated. Currently,
almost all studies investigating cellular responses to Candida
infection have been carried out using myeloid or lymphoid
cells. However, given that most pathogens eﬀect through a
mucosal surface, detailed analysis of the responses of other
cell types that comprise these surfaces, particularly ECs, may
identify novel and unusual mechanisms for host-microbe
interactions. Such studies may also identify mechanisms
that enable a host to distinguish between commensal and
pathogenic microbes in general or between the commensal
and pathogenic state of individual organisms, including
C. albicans.
Several previous investigations have identiﬁed NF-κB
and MAPK signalling as the main response mechanisms
to bacterial infection in ECs [47, 48]. Further studies have
identiﬁed NF-κB as an important pathway in EC responses
to Candida infections [18, 49]. In our own recent study, we
analysed the responses of oral ECs over time to Candida
infection and identiﬁed a unique mechanism that enables
thesecellsto discriminate between theyeastand hyphalform
of C. albicans, which we believe has strong correlations as to
whether the fungus is viewed by the host as “pathogenic” or
“commensal” [40]. We conﬁrmed that the NF-κBp a t h w a y
is important in oral EC responses to this fungus. However,
we identiﬁed MAPK signalling through all three pathways as
the mechanism by which oral ECs identify when this fungus
becomes invasive and pathogenic. Whilst NF-κB signalling
increases linearly over time, MAPK activation shows a bi-
phasic response in which a transient, early response through
ERK1/2andJNKsignallinginducesc-Junactivityinresponse
to the presence of Candida (yeast or hyphae). A second
prolonged, late response induced in response to hyphae
drives further ERK1/2 and p38 signalling, activating MAPK
regulation via the MAPK phosphatase MKP1 and induces
c-Fos activity resulting in production of cytokines. Of
particular importance is that this second MAPK response
is only induced when a suﬃcient fungal hyphal burden is
present, demonstrating that a threshold level of activation
needs to be reached prior to epithelial immune activation
(Figure 2). This MAPK-based discriminatory pathway may,
therefore, provide a mechanism for epithelial tissues to
remain quiescent in the presence of low-fungal burdens
whilst responding speciﬁcally and strongly to hyphae when
burdens increase. We propose that this mechanism may
comprise a “danger response” pathway, which may be critical
in identifying when this normally commensal fungus has
become pathogenic. Failure or deﬁciencies in this “danger
response” mechanism could lead to a potentially chronic
infection that is ineﬃciently managed by the host, as no
“danger” signal would be elicited to recruit an immune
response. Thus, it appears that ECs are instrumental in dis-
criminating between the commensal and pathogenic states
of opportunistic pathogens and that this discrimination is
communicated via the MAPK pathway.
6.Candida-InducedECCytokineResponses
Recognition of Candida by host cells leads to activation of
a cytokine response proﬁle. For myeloid cells, this proﬁle
is fairly well documented and includes release of IL-12, IL-
1α/β and TNFα along with other proinﬂammatory cytokines
[17]. Although less well deﬁned, the EC eﬀector response has
to some extent been described. We and others have shown
that infected ECs produce cytokines and chemokines with a
proinﬂammatory proﬁle [37, 40, 50–52]. Among these are
included IL-1α/β, IL-6, G-CSF, GM-CSF, and TNFα as well
as the chemokines RANTES, IL-8, and CCL20. In contrast to
myeloid and lymphoid cells, however, ECs do not produce
IL-12, IFNγ, IL-4 or IL-13. What direct eﬀect these cytokines
have on epithelial protection is unclear, although, given that
these cytokines act upon both lymphoid and myeloid cells it
is likely that they are involved in activating and recruiting
these cells into the mucosal layer. For example, IL-8 will
recruit neutrophils to the epithelium, subsequently inducing
neutrophil-dependent mucosal defence against C. albicans
[37].
As well as cytokines and chemokines, Candida infection
of ECs results in an increase in expression of matrix
metalloproteases (MMPs) [53]w h i c hw i l lp l a yar o l ei n
remodelling of the epithelium and modulating the barrier
function. Infection also results in the upregulation of various
antimicrobial peptides such as β-defensins and LL-37 [54,
55]. These antimicrobial peptides have anticandidacidal
activity and play a signiﬁcant role in combating infections
and invasion as well as initiating other immune responses
[56, 57].
7. Mucosal SurfaceImmune Responses to
C. albicans
The secretion of cytokines and chemokines by ECs in
response to Candida invasion will result in the recruitment,
diﬀerentiation, and activation of a variety of immune cells,
including neutrophils, dendritic cells and T cells. The role of
neutrophils in anti-Candida mucosal immunity appears to
be twofold. As described earlier, neutrophils can induce EC-
mediated protection against C. albicans infections through
upregulation of TLR4 [37]. Neutrophils can also directly kill
Candida cells through ingestion and killing, degranulation,
or through the recently discovered Neutrophils extracellular
Traps (NETs). NETs occur as a specialised form of neu-
trophils cell death and comprise a web of chromatin “ﬁbres”
coated with serine proteases, antimicrobial proteins, and
other neutrophils contents which capture and kill C. albicans
on various surfaces [58, 59].6 Clinical and Developmental Immunology
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Figure 2: Epithelial cell recognition of C. albicans. Epithelial cells recognise C. albicans via a two-step process [40]. Initial recognition of
yeast by surface PRRs results in prolonged activation of NF-kB and an early transient activation of MAPK signalling leading to activation of
c-Jun through the ERK1/2 and JNK pathways. When the burden of hyphae passes a threshold, recognition of these hyphae triggers a second,
prolonged activation of MAPK signalling. This results in activation of MKP1 through the ERK1/2 pathway and c-Fos via p38 signalling.
NF-κB and c-Fos then play essential roles in the transcription of cytokines secreted by the epithelial cells, whilst MKP1 acts as a negative
regulator to control the activation of JNK and p38 signalling.
As well as IL-8-recruited neutrophils, secreted CCL20
will recruit the Th17 T cell subset [60]. These cells secrete
IL-17 and IL-22 and have been associated with anti-Candida
immunity [61]. Recently, dendritic cell recognition of fungi
through Dectin-1 and Dectin-2 has been shown to play
an instrumental role in driving development of Th17 cells
[62], indicating a relationship between fungal infections and
this important T cell subset. The exact role of these cells
in anti-Candida immunity is not fully understood, with
evidence to suggest both a positive [63, 64] and negative [65]
role, although it is becoming clear that cytokines secreted
by these cells, most notably IL-17 [66–68]a n dI L - 2 2[ 69],
play a signiﬁcant role in antifungal immunity. IL-17 acts
on ECs and neutrophils, functioning as a bridge between
the adaptive and innate immune responses. Its eﬀects on
ECs include induction of antimicrobial peptides, MMPs, and
other inﬂammatory mediators. The role of L-17 in anti-
Candida immunity is controversial with evidence to indicate
that it both increases [65]a n dr e d u c e s[ 67, 68] C. albicans
burdens after infection through various routes. Interestingly,
infection of peripheral blood mononuclear cells by live
C. albicans results in inhibition of IL-17 secretion resulting
from the eﬀects of C. albicans-released 5-hydroxytryptophan
metabolites [70] with a concurrent suppression of immunity
to the fungus, suggesting that IL-17 may be important in
coordinating immune responses to the fungus. IL-22 has
similar eﬀects to IL-17 on ECs but has been suggested to
control yeast cell growth, as well as controlling epithelial
layer integrity during infection [69], thus helping to control
cell numbers and invasion of the epithelium during an
infection event. The importance of the Th17 response in
mucosal immunity to Candida spp infections is underlinedClinical and Developmental Immunology 7
by several recent studies linking defects in the Th17 response
and production of IL-17 to cases of chronic mucocutaneous
candidiasis(CMC)[67,71].Thislinkisfurthersupported by
the ﬁnding that in cases of autoimmunity with neutralising
antibodies to Th17 cytokines (IL-17A, IL-17F, and IL-22),
thereisanincreasedincidenceofCMC[72].Despitethis,the
report that IL-17 may play a deleterious role in anti-Candida
immunity [65] suggests that the situation may be far more
complex in vivo.
As well as driving innate immunity and neutrophil
responses, Th17 cells have also been shown to drive antibody
responses at mucosal surfaces, in particular secretory IgA
(sIgA). In mice, Th17 cells induce an inﬂux of CD19+ B
c e l l sa n db o o s tl e v e l so fs I g Aa sw e l la se p i t h e l i a le x p r e s s i o n
of polymeric IgA receptor [73]. Increases in secreted IgA at
m u c o s a ls u r f a c e sh a v ep r e v i o u s l yb e e nr e p o r t e d[ 74], indi-
cating that this may be another mechanism by which Th17
responses mediate protection against mucosal candidiasis,
especially since sIgA antibodies can inhibit the adherence of
C. albicans to epithelial cells [75].
8. Conclusions
Until recently, our understanding of the events and mech-
anisms involved in host mucosal responses to fungal cells
was elementary. In particular, the role of ECs in these
events was considered to be relatively unimportant. Recent
advances in our knowledge of immunity have resulted in
the identiﬁcation of a novel subset of T cells that produce
cytokines targeting ECs, thus forming a direct link involved
in maintaining the mucosal barrier. Equally, the discovery
of an EC-driven mechanism for protection against Candida
infection demonstrates that these cells communicate with
immune cells and play a role in combating fungal infections.
The elucidation of an epithelial-speciﬁc mechanism for
identifying the pathogenic state of C. albicans has conﬁrmed
the importance of ECs in mediating protective mucosal
mechanisms and in discriminating commensal microbes
from pathogens. The identiﬁcation of this role for ECs may
open new avenues of research for treatments for use in
immunocompromised patients or for those with chronic
mucosal infections.
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